Castle Biosciences (NASDAQ:CSTL) Insider Sells $110,608.32 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $33.64, for a total value of $110,608.32. Following the transaction, the insider owned 48,719 shares in the company, valued at $1,638,907.16. This represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Castle Biosciences stock traded down $1.84 during trading hours on Friday, hitting $31.96. The stock had a trading volume of 381,930 shares, compared to its average volume of 376,069. The company has a 50-day moving average of $33.56 and a two-hundred day moving average of $26.85. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The company has a market cap of $976.38 million, a PE ratio of -48.42 and a beta of 0.94. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, equities research analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

A number of hedge funds have recently modified their holdings of the stock. NFSG Corp bought a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new stake in Castle Biosciences in the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in Castle Biosciences by 188.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company’s stock valued at $82,000 after acquiring an additional 1,371 shares during the period. Quantbot Technologies LP bought a new stake in Castle Biosciences in the second quarter valued at $62,000. Finally, State of Wyoming bought a new stake in Castle Biosciences in the second quarter valued at $117,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, September 26th. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a report on Friday, July 31st. Roth Capital began coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective for the company. Finally, BTIG Research lifted their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.